<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lampert R</submitter><funding>NCATS NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><pagination>595-605</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10193262</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>8(6)</volume><pubmed_abstract>&lt;h4>Importance&lt;/h4>Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown.&lt;h4>Objective&lt;/h4>To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity.&lt;h4>Design, setting, and participants&lt;/h4>This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reporte</pubmed_abstract><journal>JAMA cardiology</journal><pubmed_title>Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy.</pubmed_title><pmcid>PMC10193262</pmcid><funding_grant_id>MC_UP_1102/20</funding_grant_id><funding_grant_id>R01 HL125918</funding_grant_id><funding_grant_id>UL1 TR001863</funding_grant_id><funding_grant_id>107469/Z/15/Z</funding_grant_id><pubmed_authors>Ackerman MJ</pubmed_authors><pubmed_authors>Salberg L</pubmed_authors><pubmed_authors>Shah M</pubmed_authors><pubmed_authors>Eidem B</pubmed_authors><pubmed_authors>Rao R</pubmed_authors><pubmed_authors>Simone L</pubmed_authors><pubmed_authors>Bos M</pubmed_authors><pubmed_authors>Cooper R</pubmed_authors><pubmed_authors>Saarel EV</pubmed_authors><pubmed_authors>Berul CI</pubmed_authors><pubmed_authors>Nandi D</pubmed_authors><pubmed_authors>Abrahms D</pubmed_authors><pubmed_authors>Cerrone M</pubmed_authors><pubmed_authors>Abraham R</pubmed_authors><pubmed_authors>Ware JS</pubmed_authors><pubmed_authors>Masri A</pubmed_authors><pubmed_authors>Molossi S</pubmed_authors><pubmed_authors>Olshansky B</pubmed_authors><pubmed_authors>Ashley E</pubmed_authors><pubmed_authors>Wever-Pinzon O</pubmed_authors><pubmed_authors>Czosek RJ</pubmed_authors><pubmed_authors>Dziura J</pubmed_authors><pubmed_authors>Kanter R</pubmed_authors><pubmed_authors>Ommen SR</pubmed_authors><pubmed_authors>Hall K</pubmed_authors><pubmed_authors>LIVE Consortium</pubmed_authors><pubmed_authors>Webster G</pubmed_authors><pubmed_authors>Ho CY</pubmed_authors><pubmed_authors>Skinner J</pubmed_authors><pubmed_authors>Li F</pubmed_authors><pubmed_authors>Zipes DP</pubmed_authors><pubmed_authors>Ainsworth B</pubmed_authors><pubmed_authors>Link MS</pubmed_authors><pubmed_authors>McKenna WJ</pubmed_authors><pubmed_authors>Aziz P</pubmed_authors><pubmed_authors>Ferhaan A</pubmed_authors><pubmed_authors>Emery MS</pubmed_authors><pubmed_authors>Tomaselli G</pubmed_authors><pubmed_authors>Concannon M</pubmed_authors><pubmed_authors>Murphy A</pubmed_authors><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Geske JB</pubmed_authors><pubmed_authors>Law IH</pubmed_authors><pubmed_authors>Sanatani S</pubmed_authors><pubmed_authors>Estes NAM</pubmed_authors><pubmed_authors>Choudhury L</pubmed_authors><pubmed_authors>Lal AK</pubmed_authors><pubmed_authors>Colan S</pubmed_authors><pubmed_authors>James CA</pubmed_authors><pubmed_authors>Harmon KG</pubmed_authors><pubmed_authors>Burg M</pubmed_authors><pubmed_authors>Gollob MJ</pubmed_authors><pubmed_authors>Barth C</pubmed_authors><pubmed_authors>Rosenthal D</pubmed_authors><pubmed_authors>Turer A</pubmed_authors><pubmed_authors>Balaji S</pubmed_authors><pubmed_authors>Erickson C</pubmed_authors><pubmed_authors>Johnsrude C</pubmed_authors><pubmed_authors>Tardif J</pubmed_authors><pubmed_authors>Perez M</pubmed_authors><pubmed_authors>Marino BS</pubmed_authors><pubmed_authors>Wong T</pubmed_authors><pubmed_authors>Cannom D</pubmed_authors><pubmed_authors>Saberi S</pubmed_authors><pubmed_authors>Perry J</pubmed_authors><pubmed_authors>Dubin AM</pubmed_authors><pubmed_authors>Towbin J</pubmed_authors><pubmed_authors>Day SM</pubmed_authors><pubmed_authors>Kannankeril P</pubmed_authors><pubmed_authors>Lampert R</pubmed_authors><pubmed_authors>Tome Esteban MT</pubmed_authors><pubmed_authors>Semsarian C</pubmed_authors><pubmed_authors>Etheridge SP</pubmed_authors><pubmed_authors>Gray B</pubmed_authors><pubmed_authors>Popjes E</pubmed_authors><pubmed_authors>Batra A</pubmed_authors></additional><is_claimable>false</is_claimable><name>Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy.</name><description>&lt;h4>Importance&lt;/h4>Whether vigorous intensity exercise is associated with an increase in risk of ventricular arrhythmias in individuals with hypertrophic cardiomyopathy (HCM) is unknown.&lt;h4>Objective&lt;/h4>To determine whether engagement in vigorous exercise is associated with increased risk for ventricular arrhythmias and/or mortality in individuals with HCM. The a priori hypothesis was that participants engaging in vigorous activity were not more likely to have an arrhythmic event or die than those who reported nonvigorous activity.&lt;h4>Design, setting, and participants&lt;/h4>This was an investigator-initiated, prospective cohort study. Participants were enrolled from May 18, 2015, to April 25, 2019, with completion in February 28, 2022. Participants were categorized according to self-reporte</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jun</publication><modification>2025-04-18T14:33:33.652Z</modification><creation>2025-04-07T00:45:49.802Z</creation></dates><accession>S-EPMC10193262</accession><cross_references><pubmed>37195701</pubmed><doi>10.1001/jamacardio.2023.1042</doi></cross_references></HashMap>